The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending dupilumab as an add-on treatment to intranasal corticosteroids for adults with severe ...

SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim ...

More information about the 2026 AAAAI Annual Meeting can be accessed here.

A 2026 Young Physician-Scientist Award honors Uchida's work in immune-mediated gastrointestinal disease and her translation of discoveries into better patient care.

Better adherence to guidelines for food allergen introduction to infants may improve incidence of EoE and food allergy.

As of Friday, January 30, Apogee Therapeutics, Inc.’s APGE share price has dipped by 7.75%, which has investors questioning ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027Data from the ongoing parallel BROADEN2 Phase 2b atopic ...

DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market ...

Those who fail to prepare, prepare to fail.” This principle has never been more relevant than today. Businesses that fail to adapt to new compliance requirements are not spared the consequences. With ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy ...

Please provide your email address to receive an email when new articles are posted on . This CME activity explores eosinophilic esophagitis (EoE) through a multidisciplinary care lens, examining how ...